1. Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors
2. CDER (Center for Drug Evaluation and Research). 2016. Guidance for industry: safety testing of drug metabolites. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration. [accessed 2022 Dec 7]. https://www.fda.gov/media/72279/download.
3. Prediction of Creatinine Clearance from Serum Creatinine
4. EMA (European Medicines Agency). 2018. Public assessment report Biktarvy®. [accessed 2022 Dec 7]. https://www.ema.europa.eu/documents/assessment-report/biktarvy-epar-public-assessment-report_en.pdf. Last.
5. FDA (Food and Drug Administration). 2018. Biktarvy® (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use. [accessed 2022 Dec 10]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf.